Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+2.24%+5.83%+58.47%+65.65% 66.7B
+4.66%+8.90%+14.57%+85.41% 56.88B
-0.21%+2.13%+23.97%+95.17% 56.53B
+2.49%+15.01%+26.21%+119.20% 46.49B
+1.95%+6.93%+29.72%+44.01% 44.8B
+2.06%+4.68%+214.00%+883.89% 41.59B
-0.47%+9.60%+27.53%+52.88% 35.35B
+3.80%-1.00%+95.20%+66.79% 33.29B
+0.57%+4.94%-40.23%+389.82% 25.1B
Average +1.64%+3.29%+49.94%+200.31% 45.19B
Weighted average by Cap. +1.94%+3.97%+50.81%+178.91%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-